Lacosamide Vivanta (Lacosamide)

Lacosamide selectively enhances the slow inactivation of voltage‑gated sodium channels in neurons. By stabilising neuronal membranes, it reduces repetitive firing and the spread of epileptic activity, helping to control seizure episodes without significantly affecting normal neuronal signaling.

The specific dose and infusion rate of Lacosamide Vivanta are determined by the prescribing clinician based on the patient’s clinical condition, age, weight, renal function, and concomitant therapies. Healthcare professionals should follow local prescribing guidelines and adjust as needed.

The safety of lacosamide in pregnancy and lactation has not been definitively established. It is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks and discuss options with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional agents that block fast sodium channels. This can offer better seizure control for some patients, especially those who have not responded to drugs like carbamazepine or levetiracetam, while presenting a distinct side‑effect profile.

Lacosamide Vivanta should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame recommended by the manufacturer.

The product is supplied as a sterile injectable solution for intravenous infusion. Administration is performed by qualified healthcare personnel, typically over a period of 15 minutes for the initial dose, followed by maintenance infusions as directed by the treating physician.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, potentially leading to arrhythmias, as well as rare but severe skin reactions (e.g., Stevens‑Johnson syndrome) and the emergence of suicidal thoughts or behaviors. Prompt medical evaluation is essential if these occur.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid its use. Additionally, individuals with significant cardiac conduction disorders, uncontrolled severe hepatic or renal impairment, or those taking contraindicated medications should not receive Lacosamide without specialist assessment.